Preparation and evaluation of controlled release microparticles for respiratory protein therapy

Journal of Pharmaceutical Sciences

Volumn 98, Issue 8, 2009, Pages 2709-2717

  Salama, Rania O ^a   Traini, Daniela ^a   Chan, Hak Kim ^a   Sung, Adrian ^a   Ammit, Alaina J ^a   Young, Paul M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Controlled release; Dry powder inhaler (DPI); Protein delivery; Pulmonary delivery; Respiratory

Indexed keywords

BOVINE SERUM ALBUMIN; POLYVINYL ALCOHOL;

AEROSOL; ARTICLE; CELL VIABILITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOTOXICITY; DENSITY; DRUG FORMULATION; DRY POWDER; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; PARTICLE SIZE; PHYSICAL CHEMISTRY; POWDER INHALER; SPRAY DRYING;

EID: 68249124509     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21653     Document Type: Article

References (44)

1. Adjei AL, Gupta PK. editors. 1997. Inhalation delivery of therapeutic peptides and proteins, 1st edition. New York: Marcel Dekker.
2. White S, Bennett DB, Cheu S, Conely PW, Guzek DB, Gray S, Howard J, Malcolmson R, Parker JM, Roberts P, Sadrzadeh N, Schumacher JD, Seshadri S, Sluggett GW, Stevenson CL, Harper NJ. 2005. EXUBERA: Pharmaceutical development of a novel product for pulmonary delivery of insulin. Diab Technol Therap 7:896-906. (Pubitemid 43133996)
3. EXUBERA official site http://www.exubera.com/ content/con-index.jsp? setShowOn=../content/con- indx.jsp&setShowHighlightOn=../content/con-index. jsp.ed.
4. Zeng XM, Martin GP, Marriott C. 1995. The controlled delivery of drugs to the lung. Int J Pharm 124:149-164.
5. Wong JP, Yang HM, Blasetti KL, Schnell G, Conley J, Schofield LN. 2003. Liposome delivery of cipro- floxacin against intracellular Francisella tularensis infection. J Control Release 92:265-273. (Pubitemid 38366150)
6. Cook RO, Pannu RK, Kellaway IW. 2005. Novel sustained release microspheres for pulmonary drug delivery. J Control Release 104:79-90. (Pubitemid 40615237)
7. Dellamary L, Smith DJ, Bloom A, Bot S, Guo GR, Deshmuk H, Costello M, Bot A. 2004. Rational design of solid aerosols for immunoglobulin delivery by modulation of aerodynamic and release characteristics. J Control Release 95:489-500. (Pubitemid 38340499)
8. Florea BI, Thanou M, Junginger HE, Borchard G. 2006. Enhancement of bronchial octreotide absorption by chitosan and N-trimethyl chitosan shows linear in vitro/in vivo correlation. J Control Release 110:353-361. (Pubitemid 41827489)
9. Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y. 2005. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release 102: 373-381. (Pubitemid 40093760)
10. Surendrakumar K, Martyn GP, Hodgers ECM, Jansen M, Blair JA. 2003. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J Control Release 91:385-394. (Pubitemid 36980658)
11. Jaspart S, Bertholet P, Piel G, Dogne JM, Delattre L, Evrard B. 2007. Solid lipid microparticles as a sustained release system for pulmonary drug delivery. Eur J Pharm Biopharm 65:47-56. (Pubitemid 44827691)
12. Fu J, Fiegel J, Krauland E, Hanes J. 2002. New polymeric carriers for controlled drug delivery following inhalation or injection. Biomaterials 23: 4425-4433. (Pubitemid 34888047)
13. Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. 2005. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev 57:411-430. (Pubitemid 39550968)
14. Takeuchi H, Yamamoto H, Kawashima Y. 2001. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 47:39-54. (Pubitemid 32209231)
15. Kwon J-H, Lee B-H, Lee J-J, Kim C-W. 2004. Insulin microcrystal suspension as a long-acting formulation for pulmonary delivery. Eur J Pharm Sci 22:107-116.
16. Johnson KA. 1997. Preparation of peptide and protein powders for inhalation. Adv Drug Deliv Rev 26:3-15.
17. Stahl K, Claesson M, Lilliehorn P, Linden H, Backstrom K. 2002. The effect of process variables on the degradation and physical properties of spray dried insulin intended for inhalation. Int J Pharm 233: 227-237. (Pubitemid 34230435)
18. Li HY, Birchall J. 2006. Chitosan-modified dry powder formulations for pulmonary gene delivery. Pharm Res 23:941-950. (Pubitemid 43781402)
19. Grenha A, Seijo B, Remunan-Lopez C. 2005. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci 25:427-437. (Pubitemid 40853870)
20. Liao YH, Brown MB, Jones SA, Nazir T, Martin GP. 2005. The effects of polyvinyl alcohol on the in vitro stability and delivery of spray-dried protein particles from surfactant-free HFA 134a-based pressurised metered dose inhalers. Int J Pharm 304: 29-39. (Pubitemid 41427647)
21. Bosquillon C, Prat W, Vanbever R. 2004. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J Control Release 96:233-244. (Pubitemid 38481506)
22. Okamoto H, Aoki M, Danjo K. 2000. A novel apparatus for rat in vivo evaluation of dry powder formulations for pulmonary administration. J Pharm Sci 89:1028-1035. (Pubitemid 30692819)
23. Adler M, Unger M, Lee G. 2000. Surface composition of spray-dried particles of bovine serum albumin/trehalose/surfactant. Pharm Res 17:863-870. (Pubitemid 30666969)
24. Seville PC, Li HY, Learoyd TP. 2007. Spray-dried powders for pulmonary drug delivery. Crit Rev Ther Drug Carrier Syst 24:307-360.
25. Elversson J, Millqvist-Fureby A. 2005. Aqueous two-phase systems as a formulation concept for spray-dried protein. Int J Pharm 294:73-87. (Pubitemid 40467569)
26. Yamamoto A, Yamada K, Muramatsu H, Nishinaka A, Okumura S, Okada N, Fujita T, Muranishi S. 2004. Control of pulmonary absorption of watersoluble compounds by various viscous vehicles. Int J Pharm 282:141-149. (Pubitemid 39178491)
27. Wang MY, Yu YT, Chang TMS. 2005. New method for preparing more stable microcapsules for the entrapment of genetically engineered cells. Artif Cells Blood Substit Immobil Biotechnol (formerly known as Artif Cells Blood Substit Immob Biotechnol) 33:257-269.
28. Kimura T, Okuno A, Miyazaki K, Furuzono T, Ohya Y, Ouchi T, Mutsuo S, Yoshizawa H, Kitamura Y, Fujisato T, Kishida A. 2004. Novel PVA-DNA nanoparticles prepared by ultra high pressure technology for gene delivery. Mater Sci Eng C 24:797-801.
29. Ramires PA, Milella E. 2002. Biocompatibility of poly(vinyl alcohol)-hyaluronic acid and poly(vinyl alcohol)-gellan membranes crosslinked by glutaraldehyde vapors. J Mater Sci: Mater Med 13:119-123. (Pubitemid 34145364)
30. Rowe RC, Sheskey PJ, Owen SC. 2006. Handbook of pharmaceutical excipients, 5th edition. Great Britain: Pharmaceutical Press; and Washington, DC: American Pharmacists Association.
31. Hinds WC. 1999. Aerosol technology, 2nd edition. New York: John Willey & Sons.
32. Chew NYK, Bagster DF, Chan HK. 2000. Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders. Int J Pharm 206:75-83.
33. Chew NYK, Chan HK. 2001. Use of solid corrugated particles to enhance powder aerosol performance. Pharm Res 18:1570-1577.
34. Bustami RT, Chan H-K, Dehghani F, Foster NR. 2000. Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide. Pharm Res 17:1360-1366. (Pubitemid 32109487)
35. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63. (Pubitemid 14203433)
36. Weyermann J, Lochmann D, Zimmer A. 2005. A practical note on the use of cytotoxicity assays. Int J Pharm 288:369-376. (Pubitemid 40038590)
37. Widdicombe JH. 2002. Regulation of the depth and composition of airway surface liquid. J Anat 201: 313-318. (Pubitemid 35244050)
38. Franz TJ. 1975. Percutaneous absorption-Relevance of in vitro data. J Invest Dermatol 64:190-195.
39. Pritchard JN. 2001. The influence of lung deposition on clinical response. J Aerosol Med- Deposition Clearance Effects Lung 14:S19-S26.
40. Chew NYK, Tang P, Chan HK, Raper JA. 2005. How much particle surface corrugation is sufficient to improve aerosol performance of powders? Pharm Res 22:148-152.
41. Smith IJ, Parry-Billings M. 2003. The inhalers of the future? A review of dry powder devices on the market today. Pulm Pharmacol Therp 16:79-95. (Pubitemid 36372063)
42. Salama RO, Traini D, Chan HK, Young PM. 2008. Preparation and charcaterisation of controlled release co-spray dried drug-polymer microparticles for inhalation. 2: Evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. Eur J Pharm Biopharm 70: 145-152.
43. Moore JW, Flanner HH. 1996. Mathematical comparison of dissolution profiles. Pharm Technol 20: 64, 66, 68, 72, 74.
44. Food and Drug Administration (FDA). U.S. Department of Health and Human Services, Guidance for Industry 1997; Dissolution Testing of Immediate Release Solid Oral Dosage Forms.